Am J Med. 1989 Apr 17;86(4A):94-7. doi: 10.1016/0002-9343(89)90200-3.
One hundred seventy-eight patients, aged 30 to 85, with mild-to-moderate hypertension entered a multicenter double-blind, randomized, between-patient comparison of isradipine (0.5, 1.25, or 2.5 mg twice daily) and placebo. Patients were assessed after three weeks of placebo treatment (for baseline) and after two and five weeks of active therapy. Despite a marked placebo effect, isradipine at 1.25 mg and 2.5 mg twice daily reduced blood pressure to a significantly lower level. The lowest blood pressures were recorded at four hours post-dose, and the residual antihypertensive effect at 12 hours was between 70 and 79 percent of the four-hour measurements. Isradipine did not produce more laboratory, electrocardiographic, or clinical abnormalities, or adverse events than did placebo. It is concluded that isradipine in doses of 1.25 mg and 2.5 mg twice daily is effective and well tolerated in the treatment of mild-to-moderate hypertension.
178名年龄在30至85岁之间的轻度至中度高血压患者，参与了一项多中心双盲、随机、患者间对照的研究，比较了伊拉地平（每日两次，每次0.5、1.25或2.5毫克）与安慰剂的效果。在接受三周安慰剂治疗（作为基线）后，以及在接受两周和五周的积极治疗后，对患者进行了评估。尽管存在明显的安慰剂效应，但每日两次服用1.25毫克和2.5毫克的伊拉地平可将血压显著降低至更低水平。服药后四小时记录到最低血压，12小时的残余降压效果为四小时测量值的70%至79%。与安慰剂相比，伊拉地平并未产生更多的实验室、心电图或临床异常情况，也未出现更多不良事件。得出的结论是，每日两次服用1.25毫克和2.5毫克的伊拉地平在治疗轻度至中度高血压方面有效且耐受性良好。
